Marsh Linda
Known title: DirectorCIK: 0001765204
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FLGT compared to PRPO in cancer diagnostics sector. A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.
Transaction History
| ASTH | ▲ Buy | Grant | 4,525 | $0 | 6/10/2026 | View on chart |
| FLGT | ▲ Buy | Grant | 11,117 | $0 | 5/14/2026 | View on chart |
| ASTH | ▲ Buy | Option Exercise | 20,000 | $364K | 11/3/2025 | View on chart |
| ASTH | ▼ Sell | Tax Withholding | 11,033 | $364K | 11/3/2025 | View on chart |
| ASTH | ▲ Buy | Grant | 6,449 | $0 | 6/11/2025 | View on chart |
| FLGT | ▲ Buy | Grant | 8,982 | $0 | 5/15/2025 | View on chart |
| ASTH | ▲ Buy | Option Exercise | 11,000 | $169K | 9/10/2024 | View on chart |
| ASTH | ▼ Sell | Tax Withholding | 3,522 | $169K | 9/10/2024 | View on chart |
| ASTH | ▲ Buy | Grant | 3,564 | $0 | 8/13/2024 | View on chart |
| FLGT | ▲ Buy | Grant | 8,000 | $0 | 5/16/2024 | View on chart |
| ASTH | ▲ Buy | Grant | 3,650 | $0 | 12/15/2023 | View on chart |
| FLGT | ▲ Buy | Grant | 5,059 | $0 | 5/18/2023 | View on chart |
| ASTH | ▼ Sell | Other | 270,081 | $9.5M | 3/14/2023 | View on chart |
| ASTH | ▲ Buy | Option Exercise | 62,500 | $625K | 3/9/2023 | View on chart |
| FLGT | ▲ Buy | Grant | 1,600 | $0 | 8/1/2022 | View on chart |
| ASTH | ▼ Sell | Open Market | 250,000 | $9.3M | 6/17/2022 | View on chart |
| FLGT | ▲ Buy | Grant | 2,000 | $0 | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Astrana Health Forms Multi-State Partnership With Verda Healthcare
Astrana Health announced a multi-state partnership with Verda Healthcare to expand culturally tailored care in underserved U.S. communities. This move aims to broaden the company's reach, though some market observers note the stock may already reflect the value of this new agreement. The company also scheduled its Q3 2026 financial results release, keeping investors focused on upcoming performance metrics.
Astrana Health Forms Multi-State Partnership With Verda Healthcare. Astrana Health announced a multi-state partnership with Verda Healthcare to expand culturally tailored care in underserved U.S. communities. This move aims to broaden the company's reach, though some market observers note the stock may already reflect the value of this new agreement. The company also scheduled its Q3 2026 financial results release, keeping investors focused on upcoming performance metrics.